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There is evidence that leukocytosis is associated with an increased risk of first thrombosis in patients with
polycythemia vera (PV) and essential thrombocythemia (ET). Whether it is a risk factor for recurrent throm-
bosis too is currently unknown. In the frame of a multicenter retrospective cohort study, we recruited
253 patients with PV (n 5 133) or ET (n 5 120), who were selected on the basis of a first arterial (70%) or
venous major thrombosis (27.6%) or both (2.4%), and who were not receiving cytoreduction at the time of
thrombosis. The probability of recurrent thrombosis associated with the leukocyte count recorded at the
time of the first thrombosis was estimated by a receiver operating characteristic analysis and a multivari-
able Cox proportional hazards regression model. Thrombosis recurred in 78 patients (30.7%); multivariable
analysis showed an independent risk of arterial recurrence (hazard ratio [HR] 2.16, 95% CI 1.12–4.18) in
patients with a leukocyte count that was >12.4 3 109/L at the time of the first thrombotic episode. The prog-
nostic role for leukocytosis was age-related, as it was only significant in patients that were aged <60 years
(HR for arterial recurrence 3.35, 95% CI 1.22–9.19). Am. J. Hematol. 85:97–100, 2010. VC 2009 Wiley-Liss, Inc.
Introduction
Polycythemia vera (PV) and essential thrombocythemia
(ET) are typically complicated by arterial or venous throm-
bosis, which may be the inaugural presentation or compli-
cate the course of disease [1]. Advanced age and a prior
history of thrombosis are the main risk factors for vascular
complications [1–6]. More recently, leukocytosis has been
reported as an independent risk factor for thrombosis in
both PV and ET [6–13]. In a previous article, we evaluated
a cohort of patients with PV and ET who had suffered at
least one thrombotic event; we showed that age >60 years
is also an independent risk factor for recurrences, and
cytoreduction significantly protects against novel events
[14]. In this study, we investigated the prognostic role of
leukocytosis that was registered at the time of the first
event to predict future recurrent thrombotic events.
Patients and Methods
Study patients. A retrospective study was conducted using the
medical records of 494 patients with PV and ET who were diagnosed at
one of the hematological centers of GIMEMA (Gruppo Italiano Malattie
Ematologiche dell’Adulto) from January 1985 to December 2005. The
main criterion for inclusion in the study was that all 494 individuals had
suffered at least one major thrombotic event related to their haemato-
logical disease. Details of the procedure used to recruit the cohort
have been reported elsewhere [14]. In this analysis, we only investi-
gated the patients who were not receiving any cytoreductive treatment
and had a recorded white blood cell (WBC) count at the time of the initial
thrombosis.
Definition of the events and of the risk factors. A thrombotic event
related to the patient’s hematologic disease was defined as an event
that occurred following diagnosis and referral to the specialized hema-
tological center, or an event that occurred no earlier than 2 years pre-
ceding the diagnosis. Thrombotic events that occurred more than 2
years before the hematologic disease diagnosis were considered to be
remote thromboses.
The major thrombotic events of interest were ischemic stroke, tran-
sient ischemic attack (TIA), acute myocardial infarction, unstable
angina pectoris, peripheral arterial thrombosis, retinal artery or vein
occlusion, deep venous thrombosis (including thrombosis of cerebral
and splanchnic veins), pulmonary embolism, and superficial venous
thrombosis. Our definition of acute coronary syndrome encompasses
acute myocardial infarction as well as unstable angina pectoris. We
consider cerebrovascular disease to include ischemic stroke as well as
TIA. Splanchnic venous thrombosis included occlusion of the hepatic,
portal, mesenteric, and splenic veins. Diagnosis of the first or a subse-
quent major thrombotic event was only accepted, if objectively proven
or in the case of medical documentation that unambiguously confirmed
the occurrence of angina or a TIA, as previously described [14]. Micro-
circulatory events, including vascular headaches, dizziness, visual dis-
turbances, sensations of burning pain in the palms of the hands and
soles of the feet, distal paresthesia and acrocyanosis, were not consid-
ered as events of interest.
Vascular risk factors included smoking habit, hypercholesterolemia,
hypertension, diabetes mellitus, and chronic atrial fibrillation. Leukocy-
tosis was defined as the upper quartile of the WBC count for those
patients who did not receive cytoreduction at the time of their first
thrombosis.
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Statistical methods. Differences in the proportions were estimated
using the Fisher’s exact test (statistical significance threshold set at P
< 0.05).
A preliminary univariable estimate of the association of the WBC
count with the probability of future recurrent thrombosis was per-
formed by a receiver operating characteristic (ROC) analysis, to
select a cut-off value to be employed in the multivariable model.
The probability of recurrence as a function of time was estimated
according to the method of Kaplan and Meier, analyzing the interval
between the initial thrombosis and a recurrent thrombotic event
(uncensored observations), or the duration until death, or the time
elapsed until the patient’s final visit to the center (censored obser-
vations). The probability of recurrence was compared between
groups using the log-rank test (statistical significance threshold at
P < 0.05), and the relative risk of recurrence was estimated as a
hazard ratio (HR) using a Cox proportional hazards regression
model. The HR was adjusted using recurrence as the dependent
variable, and the selected covariates were gender, diagnosis (PV or
ET), age at the time of the initial thrombosis (>60 or <60 years),
presence of one or more vascular risk factors, history of remote
thromboses, type of first thrombosis (arterial or venous), hematolog-
ical parameters at the time of the first thrombosis, and type of treat-
ment following thrombosis. The haematological parameters used in
the multivariable model as putative risk factors were hematocrit,
WBC count, and a platelet count that was higher than the respec-
tive upper quartile. The treatment used within our sample included
antithrombotic prophylaxis using antiplatelet agents, or long-term
oral anticoagulants, any type of pharmacological cytoreductive treat-
ment, and phlebotomy.
Statistical analyses were performed using the HLSTAT software
(Addinsoft, Paris, France) for the ROC analysis, the GraphPad PRISM
3.0 software (GraphPad Software, San Diego, CA) for univariable
methods, and the GB-STAT V6.5 software (Dynamic Mycrosystems,
Silver Spring, MD,) for multivariable testing.
Results
Study patients
We investigated 253 patients who had suffered at least
one major thrombotic event and who, at the time of the ini-
tial thrombotic event, were not receiving any cytoredutive
treatment. In 194 of them, thrombosis occurred as herald-
ing event of the myeloproliferative neoplasm. In the remain-
ing 59 patients who were asymptomatic at the time of diag-
nosis and experienced thrombosis during the follow up,
cytoreduction had not been prescribed after diagnosis by
the care physicians, because in those with PV phlebotomy
was considered effective in controlling the haematocrit
value, or because in those with ET the platelet count was
lower than 1,500 3 109/L.
The clinical characteristics of patients are shown in
Table I. Two-thirds of the initial thromboses were arterial
(Table II): The thrombosis was associated with cerebrovas-
cular disease in 108 of the patients (42.6%), acute coro-
nary syndrome in 48 of the patients (18.9%), and periph-
eral arterial occlusion in 24 of the patients (9.4%). The first
event was a venous thrombosis in 76 of the patients (30%),
including those with either a cerebral (n 5 2) or an abdomi-
nal vessel (n 5 19) involvement.
Following thrombosis, most patients received therapy
with antiplatelet agents and/or cytoreduction (Table I). One
hundred and ninety-four of the patients (76.6%) received
antiplatelet agents, while 36 of the patients (14.2%) were
prescribed long-term treatment (over one year) with vita-
min k antagonists. Six of the patients (2.4%) received both
antiplatelet and vitamin k antagonists. One hundred and
fifty-eight of the patients (62.4%) were prescribed cytore-
ductive agents, namely hydroxyurea (83.6%), pipobroman
(6.3%), busulphan (5.7%), interferon (2.5%), and anagre-
lide (1.9%). Overall, 150 of the patients (59.2%) received
a combined treatment that included both a cytoreductive
agent and an antithrombotic drug.
Recurrent thrombosis
Seventy-eight of the patients (30.8%) had a first recurrent
thrombotic event over a total observation time of 1,602
patient-years following the first thrombosis (median 5.5),
with an incidence of events of 4.8% patient-years. The ob-
servation time exceeded 5 years for 141 patients (55.7%)
and 10 years for 50 patients (19.7%).
The second thrombotic event (first recurrence) involved
arterial vessels in 46 of the patients (59% of recurrences)
and venous vessels in 32 of the patients (41%). Recur-
rence was in the form of an ischemic stroke in 12 of the
patients, TIA in 19 patients, a myocardial infarction in 6
patients, unstable angina in 5 patients, a peripheral arterial
thrombosis in 5 patients, a retinal artery occlusion in 1
patient, deep venous thrombosis of the legs in 18 patients,
a pulmonary embolism in 4 patients, superficial venous
thromboses in 6 patients, mesenteric vein thrombosis in 1
patient, and cerebral venous thrombosis in 1 patient.
TABLE I. Characteristics of the Patient Cohort
Diagnosis (no.) PV (133) ET (120) PV 1 ET (253)
Sex (M/F), no.
(% of male sex)
78/55 (58.6) 46/74 (38.3) 124/129 (49.0)
Median age at diagnosis,
years (range)
63 (18–84) 60 (21–87) 62 (18–87)
Presence of at least
one vascular
risk factor, no. (%)
83 (62.4) 70 (58.3) 153 (60.4)
Smoke, no. (%) 16 (12.0) 17 (14.1) 33 (13.0)
Hypertension, no. (%) 68 (51.1) 50 (41.6) 118 (46.6)
Hypercholesterolemia,
no. (%)
14 (10.5) 16 (13.3) 30 (11.8)
Diabetes mellitus, no. (%) 10 (7.5) 10 (8.3) 20 (7.9)
Chronic atrial fibrillation,
no. (%)
8 (6.0) 7 (5.8) 15 (5.9)
History of remote
thromboses, no. (%)
16 (12.0) 7 (5.8) 23 (9.0)
Median hematocrit at the
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than one treatment following
the initial thrombosis
Antiplatelet agents, no. (%) 103 (77.4) 97 (80.8) 200 (79.0)
Long-term oral
anticoagulation, no. (%)
22 (16.5) 20 (16.6) 42 (16.6)
Phlebotomy, no.
(% of the PV patients)
101 (75.9) – 101
Any pharmacological
cytoreduction, no. (%)a
76 (57.1) 82 (68.3) 158 (62.4)
PV, polycythemia vera; ET, essential thrombocythemia.
a
Cytoreductive treatment includes hydroxyurea, pipobroman, busulphan, inter-
feron, or anagrelide.
TABLE II. Rate of Disease-Related Thrombotic Events in the Patient Cohort
Diagnosis (no.) PV (133) ET (120) PV 1 ET (253)
First arterial thrombosis, no. (%) 93 (69.9)a 90 (75.0)a 183 (72.3)a
First venous thrombosis, no. (%) 45 (33.8)a 31 (25.8)a 76 (30.0)a
Median age at thrombosis, years (range) 63 (22–84) 61 (21–89) 63 (21–89)
First thrombosis at diagnosis of PV and
ET or during the prior 2 years, no. (%)
97 (72.9) 97 (80.8) 194 (76.6)
First thrombosis during follow-up, no. (%) 36 (27.1) 23 (19.1) 59 (23.3)
Second thrombosis during follow-up, no. (%) 44 (33.0) 34 (28.3) 78 (30.8)
Third thrombosis during follow-up, no. (%) 9 (6.7) 9 (7.5) 18 (7.1)
PV, polycythemia vera; ET, essential thrombocythemia.
a
In five of the patients with PV and one of the patients with ET, the first event
involved both arterial and venous vessels.
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After the second thrombotic event, 18 of the patients
(7.1%) experienced a third thrombosis (second recurrence),
which consisted of an ischemic stroke in two of the patients,
TIA in four patients, a myocardial infarction in two, unstable
angina in three, peripheral arterial thrombosis in one, deep
venous thrombosis of the legs in four, hepatic vein thrombo-
sis in one, and cerebral venous thrombosis in one.
Risk factors for recurrent thrombosis
The WBC counts at the time of first thrombosis ranged
between 3.1 and 24.9 3 109/L (Table I); the median value
was 10.2 3 109/L, and the upper quartile was >12.4 3
109/L. The upper quartiles of the hematocrit values and the
platelet count were >51.0% and >806 3 109/L, respectively.
We explored the univariable probability of recurrent
thrombosis associated to different WBC count cut-off val-
ues, estimating by a ROC analysis the positive likelihood
ratio (LR) between the true positives (sensitivity) and the
false positives (1 2 specificity). Using as cut-off the median
value of the WBC counts, the positive LR was 1.06 in the
overall cohort, 1.11 in the patients who were younger than
60 years, and 1.00 in the patients who were older than 60
years. Using as cut-off the upper quartile of the WBC
counts, the positive LR was 1.22 in the overall cohort, 1.86
in the patients who were younger than 60 years, and 0.81
in the patients who were older than 60 years. Applying in
the patients who were younger than 60 years as cut-off the
upper quartile of the WBC counts, the positive LR was 1.29
for recurrent venous thrombosis (sensitivity 30%, specificity
76%) and 1.97 for recurrent arterial thrombosis (sensitivity
36%, specificity 78%).
Considering the whole population, the rate of events was
not influenced by leukocytosis at the time of the first throm-
bosis (defined as WBC count over the upper quartile, i.e.,
>12.4 3 109/L); in contrast, among the patients who were
younger than 60 years, the rate of recurrence was higher
in those who had leukocytosis compared with those who
did not (44.4% vs. 21.9%, P 5 0.04). The recurrent events
that were more associated with leukocytosis were arterial
(Table III).
In a multivariable analysis that was adjusted for gender,
diagnosis, age at the time of the first thrombosis, presence
of vascular risk factors, history of remote thromboses, type
of first thrombotic event (arterial or venous), hematocrit,
leukocytosis, platelet count, and antithrombotic or cytore-
ductive treatment following the initial thrombosis, we show
that an age >60 years is an independent predictor of recur-
rences (HR, 2.00, 95% CI 1.23–3.37). Actually, the role
played by leukocytosis for recurrence reached a level that
bordered on statistical significance (HR 1.72, 95% CI 1.00–
2.95) when the model included the entire population; the
risk was significant for arterial recurrences (HR 2.16, 95%
CI 1.12–4.18), but not for venous ones (HR 1.14, 95% CI
0.43–2.98). The risk for arterial recurrences remained sig-
nificantly increased even after the exclusion of recurrent
TIA as outcome of interest (HR 3.13, 95% CI 1.22–7.98). It
is noteworthy that recurrence was significantly prevented ei-
ther by antiplatelet treatment (HR 0.38, 95% CI 0.19–0.77)
or by cytoreduction (HR 0.45, 95% CI 0.28–0.73). We were
unable to establish a predictive role for vascular recur-
rences played by gender, diagnosis of PV or ET, presence
of vascular risk factors, history of remote thromboses, he-
matocrit value or platelet count (data not shown).
After the second thrombotic event, the leukocyte number
did not significantly influence the risk for a further episode
(HR 2.60, 95% CI 0.80–8.42).
In the subgroup of younger patients (<60 years), a WBC
of >12.4 3 109/L was an independent predictor of arterial
recurrences (HR 3.35, 95% CI 1.22–9.19), but not for ve-
nous events (HR 2.87, 95% CI 0.40–20.53); no significant
risk associated with leukocytosis was noticed among the
older patients (>60 years).
Discussion
Leukocytosis has been reported to be an independent
risk factor for thrombosis in both PV and ET [6–13]. This is
in keeping with the well-established relationship in the
general population where the increased leukocyte count
predicts a first or a recurrent coronary heart disease and
ischemic stroke [15–18]. Cytoreductive therapy with hydrox-
yurea, which leads to a decrease in the WBC count, has a
protective effect on the incidence of thrombosis both in PV
and ET [7,14], which further supports a role for leukocyto-
sis in the occurrence of a thrombotic event. In line with this
concept are the results of the PT-1 randomized clinical trial
where hydroxyurea was tested against anagrelide, which
specifically inhibits platelet production and leaves the leuko-
cyte number unaffected. The investigators showed a signifi-
cant decrease in the number of arterial events in the
patients with ET treated with hydroxyurea compared with
the patients treated with anagrelide, namely in the group of
the JAK2 V617F-positive patients, and it is possible that
these results are due to the control of the leukocyte num-
ber by hydroxyurea [19,20]. The biological plausibility of the
role of leukocytes in thrombogenesis, that is, associated
with these disorders has been confirmed by many studies
that all indicate increased neutrophil and platelet activation,
increased platelet–leukocyte aggregates, endothelial dam-
age, and eventually increased levels of blood hypercoagul-
ability markers [21,22].
The presence of the somatic JAK2 V617F mutation influ-
ences both the number of leukocytes and their activation,
particularly when the allele burden is more pronounced
[23,24], and has been reported to be associated with an
increased risk for thrombosis [23–26]. Thus, it is very likely
that the JAK 2 mutation exerts its thrombogenic role via
leukocyte number and activation. The aforementioned data
refer to a correlation between baseline leukocytosis and
TABLE III. Rate of Recurrent Events in the Patient Cohort According to Age and to White Blood Cell (WBC) Count Over the Upper Quartile at the






P WBC >12.4 3
109/L versus WBC
<12.4 3 109/L
All patients Recurrent thrombosis, no. (%) 78/253 (30.8) 23/63 (36.5) 55/190 (28.9) 0.27
Recurrent arterial thrombosis, no. (%) 49/253 (19.3) 16/63 (25.3) 33/190 (17.3) 0.19
Recurrent venous thrombosis, no. (%) 29/253 (11.5) 7/63 (11.2) 22/190 (11.6) 1.00
<60 years Recurrent thrombosis, no. (%) 30/109 (27.5) 12/27 (44.4) 18/82 (21.9) 0.04
Recurrent arterial thrombosis, no. (%) 20/109 (18.3) 9/27 (33.3) 11/82 (13.4) 0.04
Recurrent venous thrombosis, no. (%) 10/109 (9.2) 3/27 (11.1) 7/82 (8.5) 0.78
>60 years Recurrent thrombosis, no. (%) 48/144 (33.3) 11/36 (30.5) 37/108 (34.2) 0.83
Recurrent arterial thrombosis, no. (%) 29/144 (20.1) 7/36 (19.4) 22/108 (20.3) 1.00
Recurrent venous thrombosis, no. (%) 19/144 (13.2) 4/36 (11.1) 15/108 (13.9) 0.78
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the first thrombotic event registered in the follow-up. In our
article, we explored whether leukocytosis could also be an
additional risk factor for recurrent thrombosis.
In a previous study cohort, patients with PV or ET show-
ing a substantial homogeneity with respect to age, pres-
ence of vascular risk factors, and the nature of their first
clinical manifestation, did not show any difference in the
risk of recurrence [14]. Therefore, the analysis performed in
this article grouped PV and ET patients into a single cate-
gory. Multivariable analysis adjusted for a number of poten-
tial confounding factors confirmed that an age over 60
years at the time of the first thrombotic event is associated
with a risk of recurrence that is double that of patients
aged less than 60 years. Moreover, the presence of leuko-
cytosis at the time of first thrombosis doubled the risk for
an arterial but not a venous recurrence. Remarkably, cytor-
eduction was highly protective halving the incidence of recur-
rent events. The risk for arterial recurrence associated with leu-
kocytosis was definitely more pronounced among the younger
patients (3.3-fold), suggesting that older age is such a strong
risk factor that it obscures the role of other predictors.
In conclusion, this study aimed to search the risk factors
that predict recurrences in PV and ET, we found that leuko-
cytosis has an impact on the occurrence of subsequent
events. This information is of clinical importance, as it sug-
gests that to avoid recurrences cytoreductive therapy after
the first event should be aimed at normalizing leukocytes,
and calls for prospective randomized trials specifically
designed to investigate this issue.
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